Speculative Biotech Firms Remain Popular Takeover Targets
March 17 2011 - 7:35AM
Marketwired
M&A activity in the healthcare sector has been on the upswing
in recent quarters. Going forward, larger healthcare firms are
expected to continue searching for smaller, more speculative
companies which are focusing on specific treatments and specialties
in the medical sector. Recent reports suggest that not only is Big
Pharma active in acquisitions, but also larger biotech firms are
showing willingness to utilize their large resource pools to
acquire smaller firms in a race to diversify and to build their
reach. The Bedford Report examines the outlook for companies in the
Healthcare Sector and provides research reports on BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) and Allos Therapeutics, Inc.
(NASDAQ: ALTH). Access to the full company reports can be found at:
www.bedfordreport.com/2011-03-BPAX
www.bedfordreport.com/2011-03-ALTH
A recent report from Deal Search Online claims that while the
biotech sector saw a 40 percent drop in the number of M&A deals
last year, the 115 deals in 2010 amounted to $57.5 billion, a 21
percent increase over 2009. The report suggests that the last
decade saw an increase in the amount of biotech deals, led in part
by pharmaceutical companies seeking new blockbuster drugs to fill
the void left by drugs coming off patent.
The Bedford Report releases regular market updates on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
Allos Therapeutics has long been mentioned as a possible
takeover target. In late 2010, shares of the company skyrocketed
after a report from Bernstein suggested Allos was a prime takeover
candidate. Allos launched Folotyn in January 2010 to treat patients
with a relapsed form of the cancer. Allos said its fourth-quarter
net loss narrowed to $18.1 million, or 17 cents per share.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024